Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
A phase 2 trial of CD19 t-haNK in non-Hodgkin lymphoma, run by ImmunityBio, Inc., now recruiting.
Overview
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma is a phase 2 interventional study registered as NCT07125872 by ImmunityBio, Inc., with 20 participants planned, started 2025-11-11 and due to reach its primary completion in 2027-05-25. Interventions recorded: CD19 t-haNK- IV Administration.
Similar pages
not linked directly; found by shared links- TrialA Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Shares ImmunityBio and the tag pipeline.
- TrialN-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Shares ImmunityBio and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.